Pacific Biosciences of California (PACB) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Revvity (RVTY) has outperformed Pacific Biosciences of California (PACB) over the past year, gaining 68.4% versus a gain of 52.3%. Over five years, RVTY leads with a -9.6% price change compared with -90.6% for PACB. Revvity is the larger company by market cap ($16.98 billion vs $714.9 million), about 23.7 times the size.
Revvity pays a dividend yielding 0.18%, while Pacific Biosciences of California does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PACB | RVTY |
|---|---|---|
| Share price | $2.30 | $152.16 |
| Market cap | $714.91M | $16.98B |
| 1-day change | -15.44% | -0.94% |
| YTD return | +22.99% | +58.76% |
| 1-year return | +52.32% | +68.44% |
| 5-year return | -90.57% | -9.55% |
| P/E ratio (TTM) | — | 72.80 |
| Forward P/E | — | 25.82 |
| EPS (TTM) | $-0.43 | $2.09 |
| Dividend yield | 0.00% | 0.18% |
| Annual dividend | $0.00 | $0.28 |
| Revenue (latest FY) | — | $2.86B |
| Revenue growth (YoY) | — | +3.67% |
| Net income (latest FY) | — | $241.20M |
| Operating margin | — | 12.49% |
| Net margin | — | 8.45% |
| 52-week high | $3.44 | $166.25 |
| 52-week low | $1.07 | $81.22 |
| Distance from 52-week high | -33.14% | -8.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -6.09% | -10.71% |
| Average volume | 10.10M | 1.79M |
| Shares outstanding | 310.83M | 111.59M |
| Employees | 485 | 11,000 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revvity is about 23.7 times larger than Pacific Biosciences of California by market value ($16.98B vs $714.91M).
- RVTY has outperformed PACB by 16.1 percentage points over the past year.
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
PACB vs RVTY FAQ
Which is bigger, Pacific Biosciences of California or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $16.98B compared with $714.91M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, PACB or RVTY?
RVTY returned +68.44% over the past 12 months, compared with +52.32% for PACB (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Pacific Biosciences of California or Revvity?
Revvity pays a dividend yielding 0.18%, while Pacific Biosciences of California does not currently pay a regular dividend.
Are Pacific Biosciences of California and Revvity in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.